• Armata Pharmaceuticals filed an amended Form 8-K to update missing details from its April 24 director appointment disclosure.
• Daniel Gilmer was assigned to the board’s Nominating and Corporate Governance Committee, effective June 24.
• Committee cash retainer set at $5,000 for 2026, prorated from the appointment date.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Armata Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-077313), on June 24, 2026, and is solely responsible for the information contained therein.